Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
It activates two incretin hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1)
Step two: confirm your prescribed dose
Switching between medications rather than combining them offers a safer pathway if initial therapy plateaus or tolerability limits the dose
As retatrutide continues through clinical development, its full side effect profile will become clearer
To view digital features for this article go to Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a class of incretin-based therapies for the treatment of type 2 diabetes (T2D), have been shown to be highly effective for both glycaemic control and weight loss, and are associated with a low risk of hypoglycaemia [1]
